IL-6 inhibitors(Interleukin-6 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas

Respiratory DiseasesOther Diseases

Active Indication

Idiopathic Pulmonary Fibrosis

Inactive Indication

LymphedemaPost Acute COVID 19 Syndrome

Originator Organization

Teva Pharmaceutical Industries Ltd.

Active Organization

Pure Technologies Ltd.

Teva Pharmaceutical Industries Ltd.

PureTech Health Plc

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC12H11NO

InChIKeyISWRGOKTTBVCFA-FIBGUPNXSA-N

CAS Registry1093951-85-9

Clinical Trials associated with Deupirfenidone

CTRI/2023/02/050138

/ RecruitingPhase 2

A Randomized, Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).

Start Date30 Mar 2023

Sponsor / Collaborator

Puretech LYT, Inc.

NCT05321420

/ Active, not recruitingPhase 2

A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.

Start Date29 Jul 2022

Sponsor / Collaborator

Pure Technologies Ltd.

NCT04652518

/ TerminatedPhase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Start Date11 Dec 2020

Sponsor / Collaborator

Pure Technologies Ltd.

[+2]

100 Clinical Results associated with Deupirfenidone

100 Translational Medicine associated with Deupirfenidone

100 Patents (Medical) associated with Deupirfenidone

Literatures (Medical) associated with Deupirfenidone

22 Nov 2022·ACS omega

Deuterated Drugs and Biomarkers in the COVID-19 Pandemic

Review

Author: Jedlovčnik, Luka ; Massey, Thomas E. ; Jansen-van Vuuren, Ross D. ; Derdau, Volker ; Košmrlj, Janez

Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.

01 Feb 2022·Clinical pharmacology in drug development

A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium‐Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases

Article

Author: Elenko, Eric ; Lickliter, Jason D. ; Harnett, Mark D. ; Korth, Christopher C. ; Chen, Michael C.

Abstract:

LYT‐100 (deupirfenidone) is a selectively deuterated form of pirfenidone under development for the treatment of inflammatory and fibrotic diseases, including interstitial lung disease. Adverse events associated with antifibrotics can be a barrier to adoption and persistence in patients with interstitial lung diseases, most of whom are not on standard‐of‐care therapy. LYT‐100 is designed to have a differentiated pharmacokinetic (PK) profile from pirfenidone and could offer a differentiated safety profile compared to current standard‐of‐care drugs while retaining the biochemical potency and specificity of pirfenidone. We conducted a phase 1b study to ascertain the safety, tolerability, steady‐state PK profile, and food effect of LYT‐100. This was a 2‐part study. Part 1 assessed multiple ascending doses of LYT‐100 from 100, 250, 500, 750, and 1000 mg twice daily given over 5 days without titration. Part 2 assessed the effects of fed vs fasting conditions on the PK profile of a single 500‐mg dose of LYT‐100. All doses up to 1000 mg were well tolerated, with adverse events being mild and transient. Exposure was slightly lower in the fed condition. LYT‐100 was well tolerated and has a dose‐proportional PK profile. The ratio of parent to major metabolite concentration was higher than reported with pirfenidone, which is consistent with an effect of deuteration on metabolism. No maximum tolerated dose was identified up to 1000 mg twice‐daily dosing. These results support further clinical development of LYT‐100, particularly considering the adverse event profile of current standard‐of‐care drugs.

GREEN CHEMISTRY

A highly efficient Suzuki–Miyaura methylation of pyridines leading to the drug pirfenidone and its CD₃ version (SD-560)

Author: Ulanenko, Konstantin ; Gottesfeld, Ronen ; Afri, Michal ; Gottlieb, Hugo ; Tor, Andrey ; Weitman, Michal ; Hassner, Alfred ; Falb, Eliezer

The first methylation/deuteromethylation in green and nearly quantitative Suzuki–Miyaura routes to pirfenidone and its d₃ analog SD-560, at 99% isotopic purity.

News (Medical) associated with Deupirfenidone

10 Feb 2025

·medcitynews.com

Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug - MedCity News

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers. Pliant disclosed few details and said it is still reviewing data, but the clock is ticking for the company to figure out next steps for the drug and the patients in the clinical trial. The pause on the Phase 2b test is voluntary, Pliant said in its announcement after Friday’s market close. No new idiopathic pulmonary fibrosis (IPF) patients will be enrolled during this pause. Currently enrolled participants will remain in the study but will not be dosed with the experimental drug, bexotegrast. The study will remain blinded to preserve integrity of the data. Pliant said it has informed clinical trial investigators and is in the process of informing regulators. IPF is a progressive disorder in which scar tissue builds up in the lungs, leading to worsening lung function that eventually becomes fatal. The few available treatments slow IPF’s progression but do not modify the course of the disease. Bexotegrast is a small molecule designed to inhibit TGF-beta, a signaling protein that leads to the production of collagen that impairs lung function. presented by Artificial Intelligence What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations When it comes to managing inbound phone calls, underperformance has devastating cost implications. By Stephanie Baum Phase 2a results reported last year showed that after 12 weeks, the Pliant drug led to a reduction in collagen while the placebo group showed an increase in collagen. Pliant also said the reduction in collagen correlated with improvement in lung function. No safety signals were reported in this study. The trial that’s now paused is the Phase 2b portion of a Phase 2b/3 study designed to evaluate treatment with bexotegrast for 52 weeks. This placebo-controlled test was expected to post preliminary data in 2026. Over the course of a clinical trial, a data safety monitoring board, an independent body comprised of outside experts, evaluates safety and efficacy data at regular intervals. In Pliant’s announcement, the company said the board’s recommendation of a trial pause followed a prespecified data review. To Leerink Partners analyst Faisal Khurshid, the voluntary pause and the continued blinding of the trial could mean the trial did not trigger pre-specified stopping criteria for safety or efficacy. But it also means the board saw something concerning enough to recommend pausing all patient dosing, he said in a note sent to investors. Since the study did not meet pre-specified stopping criteria, Pliant may not be required to unblind the study, Khurshid said. Unblinding the study would mean all data integrity would be lost. Khurshid added that the board may be taking a conservative stance of not providing the exact reasoning to Pliant. That leaves the company to choose whether to unblind the data to learn the reason. Losing data integrity means Pliant would need to start over, assuming there is a path forward for the drug. The other choice is to maintain the blind and try to work with the board in a way that does not compromise data integrity. Sponsored Post The Funding Model for Cancer Innovation is Broken — We Can Fix It Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches. By Eve McDavid - CEO of Mission-Driven Tech “In theory we think the resolution could be something like stopping one of the dose levels, excluding certain patient types, or prohibiting certain background therapies,” Khurshid said. “Again, this is all speculation. It will be important this occurs quickly as many patients were midway through a 52-week dosing period and the handling of the dosing suspension may become an issue the longer this goes.” If the study is salvageable, moving forward would likely require a major amendment to the clinical trial protocol, Khurshid said. He added that even in an optimistic scenario, Pliant may need to restart a pivotal clinical trial program, which would mean a multi-year delay. Investors did not welcome any of these options. Shares of Pliant opened Monday at $3.02, down more than 61% from Friday’s closing price. Pliant is one of several companies working to develop new drugs for IPF. Boehringer Ingelheim is at the front with nerandomilast, a small molecule designed to inhibit phosphodiesterase 4B (PDE4B), an enzyme whose roles include regulating inflammation. After announcing this drug met the main goal of its pivotal IPF studies last September, the company said it planned to seek approvals from the FDA and other regulators around the world. Nerandomilast is also in development for a different respiratory condition, interstitial lung disease. On Monday, Boehringer reported the drug met the main goal of a Phase 3 study in this indication. Full safety and efficacy data will be released in the second quarter of this year. Meanwhile, PureTech Health is developing deupirfenidone (formerly LYT-100), which employs chemical modifications to improve the tolerability of the old IPF drug pirfenidone. In December, PureTech reported its drug met key goals of a Phase 2b study with results showing improvement in measures of lung function. Another company, Insilico Medicine, is in mid-stage clinical development with ISM001-055, a small molecule inhibitor of an enzyme called TNIK. This IPF drug candidate was discovered with Insilico’s artificial intelligence platform technology. Photo by Flickr user Dominick Guzzo via a Creative Commons license

Phase 2Phase 3Clinical Result

16 Dec 2024

·endpts.com

PureTech declares mid-stage trial win for pulmonary fibrosis drug

PureTech Health unveiled positive Phase 2b data on Monday for its idiopathic pulmonary fibrosis drug, which showed it can reduce lung function decline in patients. The drug hit the trial’s primary and secondary endpoints, with deupirfenidone showing superiority to placebo in slowing the rate of lung function decline in people with IPF as measured by forced vital capacity — defined as the amount of air a person can exhale after taking a breath in — at 26 weeks. Patients taking the investigational drug at 825 mg three times a day saw an 80.9% treatment effect. In contrast, patients taking 801 mg of pirfenidone, a standard-of-care for IPF, saw a 54.1% effect. In a secondary endpoint, there was a 99.6% probability that the pooled deupirfenidone arms of the trial were superior to placebo in slowing the rate of lung function decline when using a Bayesian analysis. Executives on a Monday investor call said that the results supported moving into a Phase 3 trial. CEO Bharatt Chowrira added on the call that based on the data, only one more trial may be necessary before the company seeks approval. PureTech’s stock $PRTC on the Nasdaq was up nearly 10% on Monday. Deupirfenidone, a deuterated form of pirfenidone, is an oral treatment that works by inhibiting IL-6, TNF-α and transforming growth factor beta, according to the National Cancer Institute. As for safety, the most common adverse events included gastrointestinal issues like nausea and dyspepsia, and the only “key” gastrointestinal adverse event seen was abdominal pain, with 14.1% of patients on the drug experiencing the issue. “We’ve looked into it,” PureTech’s VP of medical affairs Camilla Graham told investors. “There’s no signal, no cause for any concern, and we’re continuing to dig into all of these numbers.” There were discontinuations, with 187 out of 257 patients completing the trial: 42 out of 65 patients in the deupirfenidone 550 mg arm and 50 out of 64 patients in the 825 mg arm. Of the patients who completed the trial, 170 enrolled in the open-label extension portion of the trial. In response to a question about discontinuations from Endpoints News , a representative for the company said they “have just received these data and our primary focus has been assessing efficacy and the key GI adverse events,” adding that “there is nothing in the data to give us cause for concern.”

Clinical ResultPhase 3Phase 2

21 Oct 2024

·news.puretechhealth.com

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

21 October 2024 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round Financing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport's pipeline of first and best-in-class neuropsychiatric medicines PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round. The syndicate was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech also participated. Following the Series B financing, PureTech will hold equity ownership in Seaport of 36.7% on a diluted basis. The financing brings the total capital raised by Seaport to $325 million since the Company's launch in April 2024. Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of the Glyph™ technology platform, which has demonstrated clinical proof-of-concept. The programs in Seaport's pipeline use the Glyph platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects to advance clinically active drugs that were previously hindered by those limitations. Commenting on today's announcement, Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech and a member of the Seaport Board of Directors, said: "We're very pleased with Seaport's $225 million Series B financing. Led by a syndicate of top-tier investors, this milestone highlights the significant progress we're making across our portfolio. The strong support from this stellar investor group not only reinforces the value generated by our unique R&D engine but also underscores our commitment to advancing transformative therapies for patients. As we look ahead to the upcoming data readout for our internal LYT-100 (deupirfenidone) program, we're excited to continue driving innovation across our portfolio with the goal of delivering impactful treatments that address significant medical needs." The full text of the announcement from Seaport is as follows: Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated Proceeds will support key clinical milestones in Seaport's pipeline of first and best-in-class neuropsychiatric medicines BOSTON, October 21, 2024 - Seaport Therapeutics ("Seaport"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round. The syndicate was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also participated. The financing brings the total capital raised by Seaport to $325 million since the company's launch in April 2024. Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of the Glyph™ technology platform, which has demonstrated clinical proof-of-concept. "We are grateful to have the partnership of this incredible group of new and existing investors who share our commitment of delivering better medicines for those suffering from depression, anxiety and other neuropsychiatric disorders," said Daphne Zohar, Founder and CEO of Seaport Therapeutics. "Seaport is advancing novel therapeutics that have proven clinical efficacy but had previously been held back by an issue we can now address with our Glyph platform. This financing enables the important clinical work that brings us another step closer to delivering new medicines to make a difference in the lives of patients and their families." "We are excited to partner with Daphne Zohar, Steve Paul and the team at Seaport," said Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic. "We are impressed with the team's outstanding CNS clinical track record, as well as Seaport's Glyph platform and innovative pipeline. The approach to clinical development and trial design demonstrates the deep neuropsychiatric expertise around the table, which we believe offers unique advantages that will contribute to Seaport's success. We look forward to supporting the company's next phase of development." The programs in Seaport's pipeline use the Glyph platform, which is designed to enable and enhance oral bioavailability, avoid first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects to advance clinically active drugs that were previously hindered by those limitations. The most advanced therapeutic candidate in the pipeline is SPT-300, an oral prodrug of allopregnanolone that is being advanced into a Phase 2b study for major depressive disorder with or without anxious distress that has the potential to be registration-enabling. Allopregnanolone is an endogenous neurosteroid with clinically validated rapid anti-depressant and anxiolytic activity, and SPT-300 retains this activity in an oral form. "The development of important new neuropsychiatric medicines is often halted due to poor drug-like properties or unacceptable tolerability, challenges that our Glyph platform can now uniquely address," said Steve Paul, M.D., Founder and Board Chair at Seaport Therapeutics. "For instance, xanomeline was an effective drug that faced tolerability challenges, but once resolved, led to the FDA approval of Cobenfy™ (formerly KarXT) for schizophrenia. With Glyph, we believe each of Seaport's programs could create similar life-changing value for patients." SPT-320, a novel prodrug of agomelatine being advanced into Phase 1 studies for the treatment of generalized anxiety disorder (GAD), has the potential to be the first new mechanism for GAD in decades. SPT-320 uses Glyph to bypass liver first-pass metabolism and thus has the potential to lower the dose and reduce liver exposure while retaining efficacious systemic exposure of agomelatine that has been validated in multiple clinical studies in GAD. The reduction in dose has the potential to eliminate the need for liver function monitoring that has previously held back agomelatine's development in GAD. SPT-348, a prodrug of a non-hallucinogenic neuroplastogen in development for the treatment of mood and other neuropsychiatric disorders, uses Glyph to create a potential first-in-class treatment. Beyond these programs, Seaport has multiple discovery and preclinical programs underway. About the Glyph™ Platform Glyph is Seaport's proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the company's pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology and the Journal of Controlled Release supporting the Glyph platform's capabilities. See Glyph in action here. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com. Ownership Information PureTech contributed $14.4 million to the Series B financing and now holds equity ownership in Seaport of 36.7 percent on a diluted basis. Additionally, as the founder of Seaport, PureTech has a right to royalty payments on a percentage of net sales of any commercialized product as well as the right under the terms of the license agreement with Seaport to receive milestone payments upon the achievement of certain regulatory approvals and a percentage of sublicense income. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to additional milestones or royalties potentially due to PureTech, Seaport's development plans for its pipeline of therapeutics for the treatment of depression, anxiety and other neuropsychiatric disorders, potential benefits to patients, the anticipated use of proceeds from the Series B financing and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Contact: PureTech Public Relations publicrelations@puretechhealth.com Investor Relations IR@puretechhealth.com UK/EU Media Ben Atwell, Rob Winder +44 (0) 20 3727 1000 puretech@fticonsulting.com US Media Justin Chen +1-609-578-7230 jchen@tenbridgecommunications.com END MSCDXBDGBUDDGSG

Phase 1Phase 2License out/in

100 Deals associated with Deupirfenidone

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Phase 2	United States	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Argentina	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Chile	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Colombia	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Georgia	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Greece	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	India	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Malaysia	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Mexico	Pure Technologies Ltd.	29 Jul 2022
Idiopathic Pulmonary Fibrosis	Phase 2	Philippines	Pure Technologies Ltd.	29 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05321420 (ELEVATE IPF, BusinessWire) Manual	Phase 2	Idiopathic Pulmonary Fibrosis	-	Placebo TID	vqoehkkkpp(qaanfgwgau) = zlwljcszxz qjfbljfadw (dcbonoynlk, 27.84) Met View more	Positive	16 Dec 2024
				Pirfenidone 801 mg TID	vqoehkkkpp(qaanfgwgau) = uqohbonaru qjfbljfadw (dcbonoynlk, 29.13) Met View more
Biospace Manual	Not Applicable	Idiopathic Pulmonary Fibrosis	-	LYT-100	wfmoqzvolb(cvwqlpcyvd) = LYT-100 also demonstrated a 24% lower than pirfenidone iqyidexwhp (gvebhavqhv ) View more	Positive	11 Oct 2023
				pirfenidone
NCT04652518 (Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	177	deupirfenidone	ehhulhxouc(ubkqxdzrvc) = Individuals in both the treatment and placebo arms meaningfully improved walking distance on the 6MWT as compared to baseline, and no statistically significant differences between treatment groups were observed. lhxktyzmow (jmlaxtuejg ) View more	Negative	14 Jun 2022
				Placebo
Corporate Publications Manual	Phase 1	Idiopathic Pulmonary Fibrosis	49	LYT-100	znolozhtgp(naibjwskeb) = sogkpqltmv prfyjongcj (uhniramchv )	Positive	16 May 2022
				Pirfenidone	znolozhtgp(naibjwskeb) = rdarbgbctu prfyjongcj (uhniramchv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Deupirfenidone

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation